Get the Stockscreener App
20.83
1.61%
-0.34
Pre-market:
20.83
Pulse Biosciences Inc stock is traded at $20.83, with a volume of 222.65K.
It is down -1.61% in the last 24 hours and down -9.55% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
See More
Previous Close:
$21.17
Open:
$21.31
24h Volume:
222.65K
Relative Volume:
0.64
Market Cap:
$1.42B
Revenue:
$350.00K
Net Income/Loss:
$-72.78M
P/E Ratio:
-19.29
EPS:
-1.08
Net Cash Flow:
$-54.46M
1W Performance:
-9.51%
1M Performance:
-9.55%
6M Performance:
+23.04%
1Y Performance:
+21.32%
1-Day Range:
$20.51
$21.65
1-Week Range:
$19.91
$24.00
52-Week Range:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, MDLN, ALC, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
20.83 | 1.42B | 350.00K | -72.78M | -54.46M | -1.08 |
ISRG
Intuitive Surgical Inc
|
457.78 | 162.13B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
149.31 | 42.47B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
44.75 | 37.84B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
74.09 | 36.11B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
205.02 | 29.87B | 5.40B | 1.49B | 1.78B | 10.12 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Executive pay and 71% insider stake at Pulse Biosciences (NASDAQ: PLSE) - Stock Titan
MSN Money - MSN
Pulse Biosciences (PLSE) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Shares Down 7.9%What's Next? - MarketBeat
Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst CallSlideshow (NASDAQ:PLSE) 2026-04-27 - Seeking Alpha
Med-tech companies highlight PFA data as competition intensifies - BioWorld News
Pulse Biosciences Reports Strong nPulse Atrial Fibrillation Data - TipRanks
New nPulse atrial fibrillation data for Pulse Biosciences (NASDAQ: PLSE) - Stock Titan
Pulse Biosciences slips despite Q4 beat after deal to sell shares - MSN
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026 - BioSpace
How (PLSE) Movements Inform Risk Allocation Models - Stock Traders Daily
Pulse Biosciences (PLSE) Reports Promising Clinical Results for Cardiac Catheter System - GuruFocus
Assessing Pulse Biosciences (PLSE) Valuation After Positive nPulse Cardiac Catheter Study Update - Sahm
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Upd - The National Law Review
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse Cardiac Catheter System at Heart Rhythm 2026 - Investing News Network
Pulse Biosciences announces positive clinical data from Npulse cardiac catheter system - marketscreener.com
Pulse Biosciences Announces Positive Clinical Data From Npulse Cardiac Catheter System - TradingView
PLSE Stock Price, Quote & Chart | PULSE BIOSCIENCES INC (NASDAQ:PLSE) - ChartMill
Pulse Biosciences Trials And Conference Spotlight Reframe Pulse Field Ablation Story - Yahoo Finance
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - The National Law Review
Pulse Biosciences' nPulse Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - Investing News Network
Pulse Biosciences (PLSE) to Showcase Innovations at Heart Rhythm Society 2026 Meeting - GuruFocus
Pulse Biosciences Starts US Trial for Cardiac Catheter System - HarianBasis.co
Pulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation Trial - Insider Monkey
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - ChartMill
Pulse Biosciences' NPulse Technology to Be Featured at the Heart Rhythm Society 2026 Annual Meeting - 富途牛牛
Total debt per share of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Pulse (PLSE) Stock: Is It Moving in a Trend (Breakout Watch) 2026-04-18Asset Allocation - Xã Vĩnh Công
Pulse Biosciences (NASDAQ:PLSE) Trading 10.1% HigherHere's Why - MarketBeat
Pulse Biosciences to Host Analyst Event on April 25, 2026 - The Joplin Globe
Pulse Biosciences Targets Thyroid Nodules With New Device Study, Eyeing a Minimally Invasive Niche - TipRanks
Pulse Biosciences Updates 2026 Cardiac Ablation Strategy - TipRanks
Pulse Biosciences posts updated investor deck with pivotal nsPFA cardiac study details - TradingView
Pulse Biosciences (PLSE) updates investor deck with 2026 clinical goals - Stock Titan
Trading Systems Reacting to (PLSE) Volatility - Stock Traders Daily
Mizuho Securities Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Income Plays: Does Pulse Biosciences Inc have strong fundamentalsPortfolio Update Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study - Yahoo Finance
Is Pulse Biosciences’ New Leadership Structure Reframing the PLSE Cardiac Therapy Commercialization Story? - Sahm
Pulse Biosciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Can Pulse Biosciences’ (PLSE) New AF Study and C-Suite Hires Reframe Its PFA Strategy? - Yahoo Finance
Q4 2025 Pulse Biosciences Inc Earnings Call Transcript - GuruFocus
Pulse Biosciences hires Liane Teplitsky as COO - MedTech Dive
Pulse Biosciences names Liane Teplitsky as chief operating officer By Investing.com - Investing.com Australia
Pulse Biosciences, Inc. (PLSE) stock price, news, quote and history - Yahoo Finance Singapore
Pulse Biosciences Strengthens Executive Leadership Team - Investing News Network
Pulse Biosciences appoints new COO to advance commercialization - TipRanks
Pulse Biosciences Appoints Liane Teplitsky as Chief Operating Officer Effective April 8, 2026 - Minichart
Liane R. Teplitsky named Chief Operating Officer at Pulse Biosciences - TradingView
Pulse Biosciences (PLSE) hires new COO with large inducement equity grants - Stock Titan
Pulse Biosciences Names Liane Teplitsky Chief Operating Officer - marketscreener.com
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.10%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):